Supplemental Online Content

Haslam A, Lythgoe MP, Greenstreen Akam E, Prasad V. Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020. JAMA Netw Open. 2021;4(11):e2135123. doi:10.1001/jamanetworkopen.2021.35123

eFigure. QALY ICER, by Study Funding Source, and Common Thresholds for Cost-Effectiveness Studies From a US Perspective

This supplemental material has been provided by the authors to give readers additional information about their work.
| Drug                                    | Category     |
|-----------------------------------------|--------------|
| Bevacizumab - ovarian                   |              |
| Niraparib - ovarian                     |              |
| Abiraterone acetate - prostate          |              |
| Palbociclib - breast                    |              |
| Atezolizumab - SCLC                     |              |
| Abiraterone acetate - prostate          |              |
| Apalutamide - prostate                  |              |
| Palbociclib - breast                    |              |
| Niraparib - ovarian                     |              |
| Avelumab - RCC                          |              |
| Ribociclib - breast                     |              |
| Encorafenib - CRC                       |              |
| Cabozantinib - HCC                      |              |
| Ribociclib - breast                     |              |
| Elotuzumab - multiple myeloma           |              |
| Nivolumab - HNSCC                       |              |
| Rucaparib - ovarian                     |              |
| Durvalumab - NSCLC                      |              |
| Atezolizumab plus bevacizumab - HCC     |              |
| Osimertinib - NSCLC                     |              |
| Abiraterone acetate - prostate          |              |
| Cabozantinib - HCC                      |              |
| Osimertinib - NSCLC                     |              |
| ixazomib - multiple myeloma             |              |
| Pembrolizumab plus axitinib - RCC       |              |
| Osimertinib - NSCLC                     |              |
| Atezolizumab - breast                   |              |
| Atezolizumab - NSCLC                    |              |
| Daratumumab - multiple myeloma          |              |
| Regorafenib - HCC                       |              |
| Pembrolizumab - urothelial              |              |
| Pembrolizumab - NSCLC                   |              |
| Olaparib - ovarian                      |              |
| Pembrolizumab plus axitinib - RCC       |              |
| Atezolizumab - NSCLC                    |              |
| Atezolizumab plus bevacizumab - HCC     |              |
| Trifluridine and tipiracil - CRC        |              |
| Pembrolizumab - NSCLC                   |              |
| Nivolumab - RCC                         |              |
| Nivolumab - HNSCC                       |              |
| Nivolumab - HNSCC                       |              |
| Pembrolizumab - NSCLC                   |              |
| Pembrolizumab - NSCLC                   |              |
| Nivolumab plus ipilimumab - RCC         |              |
